Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Subramaniam Malarkannan PhD
Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Versiti Inc
8727 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:
1983 BS, The American College, Madurai, India
1985 MS, The American College, Madurai, India
1987 M. Phil, Madurai Kamaraj University, Madurai, India
1992 Ph. D, Madurai Kamaraj University, Madurai, India

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
01/1991 - 12/1992 Visiting Fellow, Department of Pathology, University of Geneva, Geneva, Switzerland
06/1992 - 06/1998 Postdoctoral Fellow, Department of Molecular and Cell Biology, Division of Immunology, University of California, Berkeley, CA
07/1998 - 02/2000 Associate Specialist, Molecular mechanism of cryptic epitope generation, Division of Immunology, University of California, Berkeley, CA

FACULTY APPOINTMENTS:
03/2000 - 2006 Associate Investigator, Blood Research Institute, Laboratory of Molecular Immunology, Blood Center of Wisconsin, Milwaukee, WI 53226
03/2000 - 06/2007 Assistant Professor of Medicine, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226
12/2006 - Present Investigator, Blood Research Institute, Laboratory of Molecular Immunology, Blood Center of Wisconsin, Milwaukee, WI 53226
07/01/2007 - 06/31/2014 Associate Professor of Medicine, Department of Medicine, Hematology and Oncology, MCW
02/14/2014 - Present Senior Investigator, Blood Research Institute
03/01/2014 - Present Executive Council Member, Drug Development and Repurposing Initiative, CTSI, MCW
07/01/2014 - Present Professor of Microbiology and Molecular Genetics, MCW
07/01/2014 - Present Professor of Medicine, Department of Medicine, MCW
09/01/2014 - Present Professor of Pediatrics, Pediatrics, Hematology, Oncology and Transplantation, MCW

AWARDS AND HONORS:
1985 Distinction and second rank in M. Sc in the class of 1985
1986 - 1990 Junior and Senior Research Fellow of Council of Scientific and Industrial Research, Government of India
1986 Distinction in M. Phil in the class of 1986
1990 - 1991 Senior Graduate Fellow, Department of Science and Technology, Government of India
1991 - 1992 Postgraduate Fellow, Indo‐Swiss Collaboration in Biotechnology, ETH, and Zurich, Switzerland
1992 - 1995 Postdoctoral Fellow, WHO, Geneva, Switzerland (declined)
1992 - 1993 Postdoctoral Fellow, Cancer Research Coordination Committee, University of California at Berkeley
1993 - 1995 Postdoctoral Fellow, American Cancer Society (California Chapter)
1997 - 1998 Postdoctoral Fellow, Cancer Research Coordination Committee, University of California at Berkeley
2002 - 2007 International ROTRF Scholar Award, Roche Organ Transplantation Research Foundation, Roche Inc. Switzerland
2002 - 2007 ACS Research Scholar Award, American Cancer Society (National Chapter)
2002 - 2004 Young Investigator Award, American Society for Blood and Marrow Transplantation, National Chapter, Atlanta, GA, USA
2007 - 2009 Adhoc Member, Innate Immunity and Inflammation Study Section, NIAID. NIH
2009 - Present Full Member, Innate Immunity and Inflammation Study Section, NIAID, NIH
09/01/2013 - 08/31/2014 Springboard Award, Alex Lemonade Stand Foundation

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
1986 - 1992 The Indian Immunology Society (Member)
1991 - 1992 European Network of Immunology Institutes (Member)
1992 - Present The Association for the Advancement of Science (Member)
2001 - Present American Association of Immunologists (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorship
2006 Seminars in Immunology
2006 Vol 18:3, titled ‘NK Cell Development and Function: Missing‐Self Revisited’
Journal Review
2000 Journal of Immunology
2001 Blood
2004 Biology of Blood and Marrow Transplantation
2006 Bone Marrow Transplantation
2007 Molecular Immunology
2008 Innate Immunity
2008 Cancer Gene Therapy
2009 Nature‐Signaling Gateway
2009 Chronobiology International
2009 PloS Biology, PloSOne
2010 PNAS

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
06/2002 - Present Member, Seminar Committee, Blood Research Institute
06/2004 - Present Member, Cancer Center Grants Committee, Medical College of Wisconsin
08/2004 - 2007 Member, Radiation Safety Committee, Blood Research Institute
08/2007 - Present Chair, Radiation Safety Committee, Blood Research Institute
09/2010 - Present Member, External Advisory Committee, BEST Grant, STEM Program of the NSF, Milwaukee Area Technical College

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2004 External Member, Grant Review Committee, Italian Society for Cancer Research, Italy
2008 Full‐Member, NIAID‐Innate Immunity and Inflammation (III) Study Section, NIH
2009 External Member, Grant Review Committee, Agency for Science, Technology and Research (A*STAR), Biomedical Research Council of the Govt. Singapore (BMRC), Extramural Program, Singapore
2010 External Member, Grant Review Committee, Infection and Immunity Board, UK Medical Research Council (MRC), Extramural Program, UK

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Molecular mechanism of signaling co-ordination in innate lymphocytes
Source:
NIH
Role & Effort:
PI
PI:
Malarkannan
Dates:
08/01/2013 - 07/31/2017
  
Title:
Control of Inflammation in genetically-modified lymphocytes
Source:
Alex’s Lemonade Stand Foundation
Role & Effort:
PI
PI:
Malarkannan
Dates:
09/01/2013 - 08/31/2014
  
Title:
Molecular signature of inflammation
Source:
NCI
Role & Effort:
PI
PI:
Malarkannan
Dates:
03/01/2014 - 02/28/2019
  
Prior
Peer Review
Title:
The Novel Function of immunodominant minor histocompatibility antigen, H60 during GvL
Source:
Cancer Center (Malarkannan)
Dates:
01/01/2002 - 12/31/2003
  
Title:
Immunodominant mH‐Ags as Targets for GvT/GvH Reactivity
Source:
ACS‐RSG‐02‐172‐01‐LIB (Malarkannan)
Dates:
07/01/2002 - 06/30/2007
Direct Funds:
$153,600 (Major goal of this project is to analyze the efficacy of H60 molecule as a tumor target for CD8+)
  
Title:
mH‐Ags specific T‐cell mediated Immunotherapy for Hematological Malignancies
Source:
Northwestern Mutual Life Insurance (Malarkannan)
Dates:
07/01/2002 - 06/31/2004
Direct Funds:
$25,000 (The goal of this project is to investigate the efficiency of antigen specific T cells in clearing tumors)
  
Title:
Bone marrow derived allo‐NK cells for tumor targeted immunotherapy
Source:
ASBMT (Malarkannan)
Dates:
07/01/2002 - 06/30/2004
Direct Funds:
$25,000 (The goal of this project is to investigate the efficiency of bone marrow derived NK cells in clearing tumors expressing H60)
  
Title:
Role of mH‐Ags in Solid Organ Transplant Rejection
Source:
ROTRF#111662730 (Malarkannan)
Dates:
07/01/2002 - 09/31/2008
Direct Funds:
$63,792 (The major goal of this project is to determine the role of H60, a dominant minor histocompatibility antigen that is responsible for graft rejections in murine models.)
  
Title:
Robust T‐cell immunity to influenza in human populations
Source:
NIH‐NIAID‐U19 AI062627 (Gorski)
Dates:
10/01/2004 - 09/31/2009
Direct Funds:
$75,600 (Major aim of this project is to identify non‐canonical and neo‐antigenic epitopes capable of stimulating CD8+ T cells during influenza viral challenges in murine models)
  
Title:
Generation and decay of memory T cells in young, old and immuno‐compromised populations
Source:
NIH‐NIAID‐RFP‐NO1‐HHSN26600500032C (Gorski)
Dates:
10/01/2005 - 03/31/2011
Direct Funds:
$193,000 (Major goals of this project are to define the functions of NKG2D, NKG2A/CD94, and KIR receptors expressed on the antigen‐specific CD8+ human T cells during and after influenza viral infection)
  
Title:
Generation of LacZ‐inducible murine T cell hybridomas specific for human PAR peptides
Source:
Cancer Center (Mast)
Dates:
07/01/2006 - 12/31/2008
Direct Funds:
$25,000 (Major goals of this project are to generate a diagnostic method for PAR peptides expressed by tumor cells)
  
Title:
Molecular mechanisms of Natural Killer cell activation
Source:
NIH 1R01 A1064826 (Malarkannan)
Dates:
07/01/2006 - 06/30/2011
Direct Funds:
$225,000 (Major goals of this project are to define the downstream signaling events of NKG2D receptor)
  

COMMITTEE SERVICE:
Medical College of Wisconsin
2004 Member, Cancer Center Grants Committee, Medical College of Wisconsin
 

MCW TEACHING ACTIVITIES:
Medical Student Education
2001 - Present Teaching faculty, Topics in Microbiology and Immunology
2001 - Present Teaching faculty, Research conferences for Medical Students, Dept Medicine
2001 - Present Teaching faculty, Graduate course in Immunology, Dept Microbiology and Molecular Genetics
2001 - Present Teaching faculty, Medical Microbiology
2002 - Present Mentor, Minority Students Summer Research Program
 

EXTRAMURAL TEACHING:
Medical Student Education
1993 - 2000 University of California - Berkeley, Mentor, Undergraduate students in the Div. Immunol., Molecular and Cell Biology
2001 - Present University of Wisconsin, Milwaukee, Mentor, Honor’s Thesis program in Immunology for undergraduate students
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Graduate Students
PhD Students Advised
07/01/2013 - Present Alex Abel, MCW
07/01/2014 - Present Zachary Gerbec, MCW
07/01/2014 - Present Kate Dixon, MCW
 
Clinical/Research Fellows
2002 - 2004 Angela Timler, Department of Microbiology, Medical College of Wisconsin
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Postdoctoral Students
10/2001 - 2006 Dr Jeyarani Regunathan, Ph. D‐Postdoctoral Fellow
05/2003 - Present Dr Aradhana Awasthi, Ph. D‐Postdoctoral Fellow
11/2004 - 01/2005 Dr Netanya Spencer, MD Ph D‐Research Fellow
07/2005 - 06/2006 Dr Snjezana Kutlesa, Ph. D‐Postdoctoral Fellow
08/2005 - 2008 Dr Haiyan Chu, Ph. D‐Postdoctoral Fellow
10/2006 - 2008 Dr Hailong Guo, Ph D‐ Postdoctoral Fellow
10/2006 - 2007 Dr Tongbiao Zhao, Ph D‐Postdoctoral Fellow
01/2007 - Present Dr Kamalakannan Rajasekaran, Ph D, Postdoctoral Fellow
06/2007 - 2008 Dr Mathew Tinguely, MD, Postdoctoral Fellow
11/2008 - Present Dr Pawan Kumar, Ph D, Postdoctoral Fellow
02/2009 - Present Dr Ravikumar Lella, Ph D, Postdoctoral Fellow
 
Clinical/Research Fellows
2003 Eric Kohler, Rotation Student, MSTP Program, Medical Colege of Wisconsin
2004 Sandya Govindarajan, Rotation Student, Dept Microbiology, Medical Colege of Wisconsin
2006 - 2008 Mathew Tingley MD, Research Fellow, Department of Medicine, Medical Colege of Wisconsin
2006 Tyce Kearl, Rotation Student, MSTP Program, Medical Colege of Wisconsin
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Fyn/ADAP via Carma1/Bcl10/Tak1 exclusively regulates inflammatory cytokine production. Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS and Malarkannan, S. (2013) Nature Immunology 14:1127-1136
2. IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. Kumar P, Palmer MJ, Thakar MS and Malarkannan S (2013) Journal of Cancer, 4: 57-65.
3. Clinical Relevance of Natural Killer Cells Following Hematopoietic Stem Cell Transplantation. Palmer MJ, Rajasekaran K, Thakar MS and Malarkannan S (2013) Journal of Cancer, 4: 25-35.
4. IQGAP1: A regulator of intracellular spacetime. Malarkannan S, Awasthi T, Rajasekaran K, and Thakar SM (2012) J Immunol-188:2057-2063
5. IL-22 from conventional NK cells are epithelial regenerative and inflammation protective during influenza infection. Kumar P, Rajasekaran K, Thakar MS, Ouyang W and Malarkannan S (2012) Mucosal Immunology, 6:69-82.
6. Rajasekaran K, Chu H, Kumar P, Xiao Y, Tinguely M, Samarakoon A, Kim TW, Li X, Thakar MS, Zhang J, Malarkannan S. Transforming growth factor-beta-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production. J Biol Chem. 2011 Sep 09;286(36):31213-24. PMCID: PMC3173069
7. Kwun J, Malarkannan S, Burlingham WJ, Knechtle SJ. Primary vascularization of the graft determines the immunodominance of murine minor H antigens during organ transplantation. J Immunol. 2011 Oct 15;187(8):3997-4006. PMCID: PMC3357205
8. Rap1b facilitates NK cell functions via IQGAP1‐mediated signalosomes. Awasthi A, Samarakoon A, Chu H, Rajasekaran K, Quilliam L, Wodnicka M, White G, Malarkannan S. (2010) J Exp Med 207:1923‐1938
9. Functional dichotomy between NKG2D and CD28‐mediated co‐stimulation in human CD8+ T cells Rajasekaran K, Xiong V, Fong L, Gorski J, and Malarkannan S. (2010) EPup. PloSOne
10. Evasion of natural killer cells by influenza virus Guo H, Kumar P, and Malarkannan S (2010) J Leuc Biol 89:1‐6
11. Murine NKG2D Ligands: "Double, double toil and trouble" Samarakoon A, Chu H, and Malarkannan S (2009) Molecular Immunology 46:1011‐1019
12. The Functional Impairment of Natural Killer cells During Influenza Virus Infection Guo H, Kumar P, Moran TM, Garcia‐Sastre A, Zhou Y and Malarkannan S (2009) 'Outstanding Observations'‐Immunology and Cell biology 87:579‐589
13. Recognition of allo‐peptide is governed by novel anchor imposition and limited variations in TCR contact residues Reinbold C and Malarkannan S (2008) Molecular Immunology 45:1318‐26
14. p85 subunit of PI3K plays a pivotal role in the cytokine generation in NK cells Awasthi A, Chu H, Kutlesa S, Wang D, and Malarkannan S (2008) Genes Immun. 9(6):522‐35
15. Rap1b Regulates B Cell Development, Homing, and T‐Dependent Humoral Immunity Chu H, Awasthi A, White GC, Chrzanowska‐Wodnicka M, and Malarkannan S (2008) J Immunol. 181(5):3373‐83
16. Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking gimap5 Schulteis RD, Chu H, Dai X, Chen Y, Edwards B, Haribhai B, Williams CB, Malarkannan S, Hessner MJ, Glisic‐Milosavljevic S, Jana S, Kerschen EJ, Ghosh S, Wang D, Kwitek AE, Lernmark A, Gorski J, and Weiler H (2008) Blood 112:4905-14
17. The p110‐delta isoform of PI 3‐kinase plays a critical role in NK cell‐mediated tumor killing and viral clearance Guo H, Samarakoon A, Vanhaesebroeck B, and Malarkannan S (2008) J Exp Med. 205(10):2419‐35
18. Bcl10 determines the NKG2D‐mediated signaling divergence of cytotoxicity and cytokine generation in NK cells Malarkannan S, Regunathan J, Chen Y, and Wang D (2007) J Immunol. 179: 3752‐3762
19. Differential and non‐redundant roles of Phospholipase C2 and Phospholipase C1 in the terminal maturation of NK cells Regunathan J, Chen Y, Kutlesa S, Dai X, Bai L, Wen R, Wang D, and Malarkannan S (2006) J Immunol. 177: 5365‐5376
20. NK cell Development and Function: Missing‐self revisited Malarkannan S (2006) Editorial: Seminars in Immunology 18:143‐144
21. Altered‐Balance: Inhibitory Ly49 receptors regulate NKG2D‐mediated NK cell functions Malarkannan S (2006) Seminars in Immunology 18:186‐192
22. NKG2D‐mediated NK cell Function is regulated by Inhibitory Ly49 Receptors Regunathan J Chen Y, Wang D, and Malarkannan S (2005) Blood 105:233‐240
23. Minor Histocompatibility Antigens: Time for a paradigm shift? Malarkannan S (2005) Transplantation Reviews 19:1‐19
24. Minor Histocompatibility Antigens: Molecular targets for immunomodulation in tissue transplantation and tumor therapy Malarkannan S, Regunathan J, and Tranchita AM (2005) Clinical and Applied Immunology Reviews 5: 95‐109
25. Minor H Antigens: Molecular Barriers for successful Organ Transplantations Malarkannan S, and Pooler LM (2004) Ed: Drs D. Wilkes and W. Burlingham., in ‘Immunobiology of Organ Transplantation’, Chapter 7: 71‐105, Kluwer/Plenum Press.
26. Unanticipated antigens: Translation initiation at CUG with leucine Schwab SR, Shugart JA, Horng T, Malarkannan S, and Shastri N (2004) PloS Biology 11:1774‐1784
27. A single amino acid polymorphism is the Emp‐3 gene defines immunodominant CTL responses directed to the minor histocompatibility antigen, H4 Luedtke B, Tranchita A, Corbett R, Choi E Y, Roopenian D, and Malarkannan S (2003) Immunogenetics 55: 284‐295
28. Minor Histocompatibility Antigens: Molecular Targets for Adoptive Cellular Immunotherapy Malarkannan S (2002) Current Opinion in Organ Transplantation 7:1‐12
29. Real‐time T cell Profiling Identifies H60 as a Major Minor Histocompatibility Antigen in Murine Graftvs‐ Host Disease Choi E Y, Christianson G J, Malarkannan S, Joyce S, and Roopenian, D (2002) Blood 100:4259‐4264
30. Quantitative analysis of the immune response to mouse non‐MHC transplantation antigens in vivo: the H60 histocompatibility antigen, dominates over all others Choi E Y, Christianson G J, Sproule T J, Yoshimura Y, Malarkannan S, Shastri N, Joyce S, Roopenian, D (2001) J Immunol. 166: 4370‐4379
31. Generation and analysis of LacZ inducible T cell hybrids Malarkannan S, Mendoza LM, and Shastri N (2001) Methods Mol Biol. 156:265‐272
32. Identification of CD8+ T‐cell‐stimulating antigen genes in cDNA libraries Mendoza LM, Malarkannan S, and Shastri N (2001) Methods Mol Biol. 156:255‐63
33. Differences that matter: The major cytotoxic T cell stimulating minor histocompatibility antigens Malarkannan S, Horng T, Eden P, Gonzalez F, Shih P, Brouwenstijn N, Roopenian D, and Shastri N (2000) Immunity 13:333‐344
34. Presentation of out‐of‐frame peptide/MHC class I complexes by a novel translation initiation mechanism Malarkannan S, Horng T, Shih P, and Shastri N (1999) Immunity, 10:681‐690
35. The Molecular and Functional Characterization of a dominant minor H antigen, Malarkannan S, Shih P, Eden P, Horng T, Zuberi A, Christianson G, Roopenian D, and Shastri N (1998) J Immunol. 161:3501‐3509
36. The mouse mammary tumor virus env gene is the source of a CD8+ T‐cell stimulating peptide presented by a major histocompatibility complex class I molecule in a murine thymoma Malarkannan S, Serwold T, Nguyen V, Sherman LA, and Shastri N (1996) Proc Natl Acad Sci. (USA) 93:13991‐13996
37. Alloreactive CD8+ T‐cells can recognize unusual, rare, and unique processed peptide/MHC complexes Malarkannan S, Gonzalez F, Nguyen V, Adair G, and Shastri N (1996) J. Immunol. 157:4464‐4473
38. A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T‐cells Malarkannan S, Afkarian M, Shastri N (1995) J Exp Med. 182:1739‐1750
39. The role of MHC class I molecules in the generation of endogenous peptide/MHC complexes Malarkannan S, Goth S, Buchholz DR, and Shastri N (1995) J Immunol, 154: 585‐98
40. Immunodetection of biotinylated lymphocyte surface proteins by Enhanced Chemiluminescence ‐ a non‐radioactive method for cell surface protein analysis Meier T, Arni S, Malarkannan S, Poincelet M and Hoessli D C (1992) Analytical Biochemistry 204: 220‐26
41. Impairment of Alternate pathway of T‐Cell Activation in leprosy Malarkannan S, Chakkalath, H.R, and Muthukkaruppan VR (1989) J Biosciences 14:29‐35
42. The Classical and Alternate Pathway of T‐cell activation in Leprosy Muthukkaruppan VR, Chakkalath, H.R, and Malarkannan, S. (1988) Immunology Letters 19:55‐60
43. Meier T, Arni S, Malarkannan S, Poincelet M, Hoessli D. Immunodetection of biotinylated lymphocyte-surface proteins by enhanced chemiluminescence: a nonradioactive method for cell-surface protein analysis. Anal Biochem. 1992 Jul;204(1):220-6.
44. Milanovich S, Peterson J, Allred J, Stelloh C, Rajasekaran K, Fisher J, Duncan SA, Malarkannan S, Rao S. Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner. Exp Hematol. 2015 Jan;43(1):53-64.e1-8. PMCID: PMC4268405
45. Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. PLoS One. 2014;9(6):e99486. PMCID: PMC4051752
46. Abel AM, Schuldt KM, Rajasekaran K, Hwang D, Riese MJ, Rao S, Thakar MS, Malarkannan S. IQGAP1: insights into the function of a molecular puppeteer. Mol Immunol. 2015 Jun;65(2):336-49. PMCID: PMC4480615
47. Gerbec ZJ, Thakar MS, Malarkannan S. The Fyn-ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells. Front Immunol. 2015;6:472. PMCID: PMC4584950
48. Arumugam V, Bluemn T, Wesley E, Schmidt AM, Kambayashi T, Malarkannan S, Riese MJ. TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β. J Leukoc Biol. 2015 Nov;98(5):703-12. PMCID: PMC4600064
49. Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S. Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy. Front Immunol. 2016;7:176. PMCID: PMC4863891
50. Li N, Xu W, Yuan Y, Ayithan N, Imai Y, Wu X, Miller H, Olson M, Feng Y, Huang YH, Jo Turk M, Hwang ST, Malarkannan S, Wang L. Author Correction: Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci Rep. 2018 Mar 01;8(1):4054. PMCID: PMC5832769
51. Jang Y, Gerbec ZJ, Won T, Choi B, Podsiad A, B Moore B, Malarkannan S, Laouar Y. Cutting Edge: Check Your Mice-A Point Mutation in the <i>Ncr1</i> Locus Identified in CD45.1 Congenic Mice with Consequences in Mouse Susceptibility to Infection. J Immunol. 2018 Mar 15;200(6):1982-1987. PMCID: PMC5840015
52. Xu W, Hiếu T, Malarkannan S, Wang L. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 2018 May;15(5):438-446. PMCID: PMC6068175
53. Nanbakhsh A, Best B, Riese M, Rao S, Wang L, Medin J, Thakar MS, Malarkannan S. Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells. J Vis Exp. 2018 Jan 15(131). PMCID: PMC5908645
54. Fisher JB, Peterson J, Reimer M, Stelloh C, Pulakanti K, Gerbec ZJ, Abel AM, Strouse JM, Strouse C, McNulty M, Malarkannan S, Crispino JD, Milanovich S, Rao S. The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9. Leukemia. 2017 Mar;31(3):712-719. PMCID: PMC5332284
55. Abel AM, Tiwari AA, Gerbec ZJ, Siebert JR, Yang C, Schloemer NJ, Dixon KJ, Thakar MS, Malarkannan S. IQ Domain-Containing GTPase-Activating Protein 1 Regulates Cytoskeletal Reorganization and Facilitates NKG2D-Mediated Mechanistic Target of Rapamycin Complex 1 Activation and Cytokine Gene Translation in Natural Killer Cells. Front Immunol. 2018;9:1168. PMCID: PMC5985319
56. Yang C, Tsaih SW, Lemke A, Flister MJ, Thakar MS, Malarkannan S. mTORC1 and mTORC2 differentially promote natural killer cell development. Elife. 2018 May 29;7. PMCID: PMC5976438
57. Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ. Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance. Immunohorizons. 2018 Apr 01;2(4):107-118. PMCID: PMC6048965
58. Luo X, Chen J, Schroeder JA, Allen KP, Baumgartner CK, Malarkannan S, Hu J, Williams CB, Shi Q. Platelet Gene Therapy Promotes Targeted Peripheral Tolerance by Clonal Deletion and Induction of Antigen-Specific Regulatory T Cells. Front Immunol. 2018;9:1950. PMCID: PMC6136275
59. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018;9:1869. PMCID: PMC6099181
60. Yang C, Siebert JR, Burns R, Gerbec ZJ, Bonacci B, Rymaszewski A, Rau M, Riese MJ, Rao S, Carlson KS, Routes JM, Verbsky JW, Thakar MS, Malarkannan S. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat Commun. 2019 Sep 02;10(1):3931. PMCID: PMC6718415
61. Liberio N, Robinson H, Nugent M, Simpson P, Margolis DA, Malarkannan S, Keever-Taylor C, Thakar MS. Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019 Nov;66(11):e27950. PMCID: PMC6754268
62. Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta HM, Miller HE, Olson M, Rajasekaran K, Ernstoff MS, Wang D, Malarkannan S, Wang L. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Cancer Immunol Res. 2019 Sep;7(9):1497-1510. PMCID: PMC6726548
63. Reimer M Jr, Pulakanti K, Shi L, Abel A, Liang M, Malarkannan S, Rao S. Deletion of Tet proteins results in quantitative disparities during ESC differentiation partially attributable to alterations in gene expression. BMC Dev Biol. 2019 Jul 08;19(1):16. PMCID: PMC6615237
64. Kumar P, Rajasekaran K, Nanbakhsh A, Gorski J, Thakar MS, Malarkannan S. IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection. Sci Rep. 2019 Mar 21;9(1):4984. PMCID: PMC6428861
65. Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS, Malarkannan S. Erratum: Signaling by Fyn-ADAP via the carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells (Nature Immunology (2013) DOI 10.1038/ni2708)) Nature Immunology. February 2014;15(2):205.
66. Malarkannan S. Missing-self: Revisited Seminars in Immunology. June 2006;18(3):143-144.
67. Malarkannan S, Regunathan J, Timler AM. Minor histocompatibility antigens: Molecular targets for immunomodulation in tissue transplantation and tumor therapy Clinical and Applied Immunology Reviews. March 2005;5(2):95-109.
68. Malarkannan S. Minor histocompatibility antigens: Time for a paradigm shift? Transplantation Reviews. January 2005;19(1):1-19.
69. Malarkannan S. Minor histocompatibility antigens: Molecular targets for adoptive cellular immunotherapy Current Opinion in Organ Transplantation. September 2002;7(3):299-304.
70. Malarkannan S, Chakkalath HR, Muthukkaruppan VR. Impairment of alternate pathway (CD2) of T cell activation in leprosy Journal of Biosciences. March 1989;14(1):29-36.
71. Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS, Malarkannan S. Corrigendum: Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat Immunol. 2014 Jan 21;15(2):205.
72. Li N, Xu W, Yuan Y, Ayithan N, Imai Y, Wu X, Miller H, Olson M, Feng Y, Huang YH, Jo Turk M, Hwang ST, Malarkannan S, Wang L. Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci Rep. 2017 May 03;7(1):1485. PMCID: PMC5431161
73. Sitaram P, Uyemura B, Malarkannan S, Riese MJ. Beyond the cell surface: Targeting intracellular negative regulators to enhance t cell anti-tumor activity International Journal of Molecular Sciences. 1 December 2019;20(23).
74. Schloemer NJ, Abel AM, Thakar MS, Malarkannan S. In Vivo Assessment of NK Cell-Mediated Cytotoxicity by Adoptively Transferred Splenocyte Rejection. Methods Mol Biol. 2020;2097:115-123.
75. Nanbakhsh A, Malarkannan S. Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells. Methods Mol Biol. 2020;2097:107-113.
76. Chen Y, Yang M, Huang W, Chen W, Zhao Y, Schulte ML, Volberding P, Gerbec Z, Zimmermann MT, Zeighami A, Demos W, Zhang J, Knaack DA, Smith BC, Cui W, Malarkannan S, Sodhi K, Shapiro JI, Xie Z, Sahoo D, Silverstein RL. Mitochondrial Metabolic Reprogramming by CD36 Signaling Drives Macrophage Inflammatory Responses. Circ Res. 2019 Dec 06;125(12):1087-1102. PMCID: PMC6921463
77. Nanbakhsh A, Srinivasamani A, Holzhauer S, Riese MJ, Zheng Y, Wang D, Burns R, Reimer MH, Rao S, Lemke A, Tsaih SW, Flister MJ, Lao S, Dahl R, Thakar MS, Malarkannan S. <i>Mirc11</i> Disrupts Inflammatory but Not Cytotoxic Responses of NK Cells. Cancer Immunol Res. 2019 Oct;7(10):1647-1662. PMCID: PMC7428857
78. Sitaram P, Uyemura B, Malarkannan S, Riese MJ. Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity. Int J Mol Sci. 2019 Nov 20;20(23). PMCID: PMC6929154
79. Thakar MS, Kearl TJ, Malarkannan S. Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. Front Oncol. 2019;9:1529. PMCID: PMC7006459
80. Yang C, Siebert JR, Burns R, Zheng Y, Mei A, Bonacci B, Wang D, Urrutia RA, Riese MJ, Rao S, Carlson KS, Thakar MS, Malarkannan S. Single-cell transcriptome reveals the novel role of T-bet in suppressing the immature NK gene signature. Elife. 2020 May 14;9. PMCID: PMC7255804
81. Wang D, Malarkannan S. Transcriptional Regulation of Natural Killer Cell Development and Functions. Cancers (Basel). 2020 Jun 16;12(6). PMCID: PMC7352776
82. Hashemi E, Malarkannan S. Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance. Cancers (Basel). 2020 Jun 12;12(6). PMCID: PMC7352973
83. Idso JM, Lao S, Schloemer NJ, Knipstein J, Burns R, Thakar MS, Malarkannan S. Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway. Oncotarget. 2020 May 19;11(20):1799-1815. PMCID: PMC7244011
84. Yang C, Malarkannan S. Transcriptional Regulation of NK Cell Development by mTOR Complexes. Front Cell Dev Biol. 2020;8:566090. PMCID: PMC7683515
85. Malarkannan S. Molecular mechanisms of FasL-mediated 'reverse-signaling'. Mol Immunol. 2020 Nov;127:31-37. PMCID: PMC7606657
86. Gerbec ZJ, Hashemi E, Nanbakhsh A, Holzhauer S, Yang C, Mei A, Tsaih SW, Lemke A, Flister MJ, Riese MJ, Thakar MS, Malarkannan S. Conditional Deletion of PGC-1α Results in Energetic and Functional Defects in NK Cells. iScience. 2020 Sep 25;23(9):101454. PMCID: PMC7474003
87. Malarkannan S. NKG7 makes a better killer. Nat Immunol. 2020 Oct;21(10):1139-1140.
88. Malarkannan S. Molecular mechanisms of FasL-mediated 'reverse-signaling'. Mol Immunol. 2020 Nov;127:31-37. PMCID: PMC7606657
89. Nanbakhsh A, Malarkannan S. The Role of microRNAs in NK Cell Development and Function. Cells. 2021 Aug 07;10(8). PMCID: PMC8391642
90. Khalil M, Wang D, Hashemi E, Terhune SS, Malarkannan S. Implications of a 'Third Signal' in NK Cells. Cells. 2021 Jul 31;10(8). PMCID: PMC8393955
91. Hashemi E, Bjorgaard S, Wang D, Uyemura B, Riese M, Thakar MS, Malarkannan S. NK Cell Development and Function in Patients with Fanconi Anemia. Crit Rev Immunol. 2021;41(2):35-44. PMCID: PMC11536512
92. Wang D, Uyemura B, Hashemi E, Bjorgaard S, Riese M, Verbsky J, Thakar MS, Malarkannan S. Role of GATA2 in Human NK Cell Development. Crit Rev Immunol. 2021;41(2):21-33. PMCID: PMC11536496
93. Dixon KJ, Siebert JR, Wang D, Abel AM, Johnson KE, Riese MJ, Terhune SS, Tarakanova VL, Thakar MS, Malarkannan S. MyD88 is an essential regulator of NK cell-mediated clearance of MCMV infection. Mol Immunol. 2021 Sep;137:94-104.
94. Malarkannan S. Molecular mechanisms of FasL-mediated 'reverse-signaling'. Mol Immunol. 2020 Nov;127:31-37. PMCID: PMC7606657
95. Wang D, Malarkannan S. Transcriptomic perspectives of memory-like NK cells and aging. Genome Med. 2022 May 25;14(1):57. PMCID: PMC9129893
96. Khalil M, Mei A, Hashemi E, Wang D, Schumacher M, Terhune S, Malarkannan S. Method to Study Adaptive NK Cells Following MCMV Infections. Methods Mol Biol. 2022;2463:195-204.
97. Hashemi E, Mei A, Wang D, Khalil M, Malarkannan S. Methods for Isolating and Defining Single-Cell Transcriptomes of Tissue-Resident Human NK Cells. Methods Mol Biol. 2022;2463:103-116.
98. Mei A, Hashemi E, Khalil M, Wang D, Malarkannan S. Isolation of Innate Lymphoid Cells from Murine Intestinal Lamina Propria. Methods Mol Biol. 2022;2463:3-9.
99. Wang D, Burns R, Khalil M, Mei A, Hashemi E, Malarkannan S. Methods to Analyze the Developmental Trajectory of Human Primary NK Cells Using Monocle and SCENIC Analyses. Methods Mol Biol. 2022;2463:81-102.
100. Gerbec Z, Malarkannan S. NK cell-mediated immunotherapy: The exquisite role of PGC-1a in metabolic reprogramming Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance. 1 January 2021:121-142.
101. Khalil M, Malarkannan S. Innatus immunis: Evolving paradigm of adaptive NK cells. J Exp Med. 2022 Nov 07;219(11). PMCID: PMC9449531
102. Kaur K, Chen PC, Ko MW, Mei A, Chovatiya N, Huerta-Yepez S, Ni W, Mackay S, Zhou J, Maharaj D, Malarkannan S, Jewett A. The Potential Role of Cytotoxic Immune Effectors in Induction, Progression and Pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Cells. 2022 Oct 31;11(21). PMCID: PMC9656116
103. Kaur K, Chen PC, Ko MW, Mei A, Huerta-Yepez S, Maharaj D, Malarkannan S, Jewetta A. Successes and challenges in taming the beast: Cytotoxic immune effectors in amyotrophic lateral sclerosis Critical Reviews in Immunology. 2023;43(1):1-11.
104. Kaur K, Chen PC, Ko MW, Mei A, Senjor E, Malarkannan S, Kos J, Jewett A. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice. Front Immunol. 2023;14:1132807. PMCID: PMC10183580
105. Hashemi E, McCarthy C, Rao S, Malarkannan S. Transcriptomic diversity of innate lymphoid cells in human lymph nodes compared to BM and spleen. Commun Biol. 2024 Jun 25;7(1):769. PMCID: PMC11199704
106. George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2024 May;166(5):859-871.e3.
107. Kumar P, Rajasekaran K, Malarkannan S. Novel PI(3)K-p85α/p110δ-ITK-LAT-PLC-γ2 and Fyn-ADAP-Carma1-TAK1 Pathways Define Reverse Signaling via FasL. Crit Rev Immunol. 2024;44(1):55-77.
108. Kaur K, Chen PC, Ko MW, Mei A, Huerta-Yepez S, Maharaj D, Malarkannan S, Jewett A. Successes and Challenges in Taming the Beast: Cytotoxic Immune Effectors in Amyotrophic Lateral Sclerosis. Crit Rev Immunol. 2023;43(1):1-11.
109. Chen V, Zhang J, Chang J, Beg MA, Vick L, Wang D, Gupta A, Wang Y, Zhang Z, Dai W, Kim M, Song S, Pereira D, Zheng Z, Sodhi K, Shapiro JI, Silverstein RL, Malarkannan S, Chen Y. CD36 restricts lipid-associated macrophages accumulation in white adipose tissues during atherogenesis. Front Cardiovasc Med. 2024;11:1436865. PMCID: PMC11327822
110. Lauener MP, Tanaka E, Mei A, Abdossamadi S, Ostroumov E, Geltink RIK, Malarkannan S, Schultz KR. Expansion and characterization of immune suppressive CD56(bright)Perforin(-) regulatory-like natural killer cells in chronic graft-versus-host disease. Cytotherapy. 2024 Dec;26(12):1472-1483.